Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer

Cabazitaxel has been demonstrated to improve the overall survival for men with metastatic castrate-resistant prostate cancer. The purpose of this study was to determine the maximum tolerated dose for concurrent cabazitaxel with androgen deprivation and intensity modulated radiation therapy in men with high-risk prostate cancer.

Source: International Journal of Radiation Oncology * Biology * Physics - February 2, 2020 Category: Radiology Authors: Jianqing Lin, Robert B. Den, Jacob Greenspan, Timothy N. Showalter, Jean H. Hoffman-Censits, Costas D. Lallas, Edouard J. Trabulsi, Leonard G. Gomella, Mark D. Hurwitz, Benjamin Leiby, Adam P. Dicker, W. Kevin Kelly Tags: Clinical Investigation Source Type: research